Recombinant Mesocricetus auratus Delta-sarcoglycan (SGCD)

What is Delta-sarcoglycan and what is its functional role in muscle tissue?

Delta-sarcoglycan (Delta-SG) is a 35 kDa transmembrane glycoprotein that forms part of the sarcoglycan complex in the sarcolemma of muscle fibers. This protein, encoded by the SGCD gene, plays a crucial role in maintaining muscle membrane integrity and mediating connections between the extracellular matrix and the cytoskeleton . Delta-SG functions as part of a tetrameric complex with alpha-, beta-, and gamma-sarcoglycans, collectively stabilizing the dystrophin-associated protein complex (DAPC) . The absence or dysfunction of Delta-SG leads to compromised sarcolemmal integrity, resulting in muscle fiber damage, necrosis, and eventually, muscular dystrophy .

Why is the Syrian hamster (Mesocricetus auratus) used as a model for Delta-sarcoglycan research?

The Syrian hamster, particularly the BIO 14.6 strain, serves as an excellent natural model for sarcoglycan-deficient limb-girdle muscular dystrophy (LGMD) due to a spontaneous deletion in the delta-sarcoglycan gene . This model recapitulates many features of human sarcoglycanopathies, including progressive muscle degeneration and loss of sarcolemmal integrity. The use of this model offers several methodological advantages:

• It provides a consistent genetic background for studying delta-sarcoglycan deficiency

• The phenotype closely mimics human LGMD

• The model allows for testing therapeutic interventions such as gene transfer

• It enables long-term expression studies to evaluate treatment efficacy

Research has demonstrated that the BIO 14.6 hamster model can be effectively used to investigate the function of the sarcoglycan complex and assess the feasibility of gene therapy approaches for LGMD .

What techniques are most effective for expressing and purifying Recombinant Mesocricetus auratus Delta-sarcoglycan?

Expressing and purifying Recombinant Mesocricetus auratus Delta-sarcoglycan presents several technical challenges due to its transmembrane nature. Based on current research practices, the following methodological approach is recommended:

• Expression System Selection: Mammalian expression systems (HEK293 or CHO cells) are preferred over bacterial systems to ensure proper post-translational modifications, particularly glycosylation.

• Vector Design: Use vectors containing strong promoters (CMV, EF1α) and include appropriate secretion signals and affinity tags (His, FLAG, or GST) for purification.

• Purification Strategy:

  • Solubilization using mild detergents (e.g., n-dodecyl-β-D-maltoside)

  • Affinity chromatography using tag-specific resins

  • Size exclusion chromatography for increased purity

  • Storage in a Tris-based buffer with 50% glycerol at -20°C or -80°C to maintain stability

• Quality Control: Validate protein functionality using binding assays with other sarcoglycan components and assessment of glycosylation status.

For optimal results, researchers should avoid repeated freeze-thaw cycles and prepare working aliquots stored at 4°C for up to one week .

How can adenoviral vectors be optimized for Delta-sarcoglycan gene transfer in muscular dystrophy models?

Adenoviral vector optimization for Delta-sarcoglycan gene transfer requires careful consideration of several parameters to achieve effective therapeutic outcomes. Based on successful applications in the BIO 14.6 hamster model, the following methodological approach is recommended:

• Vector Design Considerations:

  • Use recombinant adenovirus serotypes with high tropism for muscle (Ad5-based vectors)

  • Include muscle-specific promoters (e.g., muscle creatine kinase) to restrict expression

  • Optimize codon usage for hamster expression

  • Include regulatory elements to enhance expression durability

• Delivery Methodology:

  • Direct intramuscular injection for localized studies

  • Systemic delivery via tail vein injection for widespread distribution

  • Timing of delivery should account for disease progression

  • Multiple injections may be required for sustained expression

• Efficacy Assessment Parameters:

  • Expression of Delta-sarcoglycan using immunohistochemistry

  • Restoration of the entire sarcoglycan complex

  • Stable association of alpha-dystroglycan with the sarcolemma

  • Reduction of morphological markers of muscular dystrophy

  • Restoration of plasma membrane integrity

Research has demonstrated that successful gene transfer results in extensive long-term expression of delta-sarcoglycan and rescue of the entire sarcoglycan complex, ultimately restoring sarcolemmal integrity in treated muscle fibers .

What are the critical parameters for developing a CRISPR/Cas9-based Delta-sarcoglycan knockout model in Mesocricetus auratus?

Developing a CRISPR/Cas9-based Delta-sarcoglycan knockout model in Syrian hamsters requires careful attention to several methodological details. While the search results don't specifically address SGCD knockout, we can extrapolate from similar approaches used for other genes in Mesocricetus auratus:

• Guide RNA Design:

  • Target conserved exonic regions of the SGCD gene

  • Select sequences with minimal off-target effects

  • Design multiple gRNAs to increase editing efficiency

  • Validate gRNA efficacy in cell culture before in vivo application

• Delivery Method:

  • Microinjection of CRISPR/Cas9 components into one-cell embryos

  • Use of Cas9 protein rather than mRNA for immediate editing

  • Careful optimization of component concentrations

• Screening and Validation:

  • PCR-based genotyping followed by sequencing

  • Protein expression analysis via Western blotting

  • Histological assessment of muscle tissue

  • Functional tests for muscle integrity and performance

• Phenotypic Characterization:

  • Comparison with natural BIO 14.6 model

  • Comprehensive muscle pathology analysis

  • Evaluation of other sarcoglycan complex components

  • Assessment of disease progression timeline

Similar approaches have been successfully employed in generating Syrian hamster models for other genes, including RAG1, where CRISPR/Cas9 was used to introduce specific mutations .

How does the BIO 14.6 hamster model compare with other muscular dystrophy models for studying Delta-sarcoglycan deficiency?

The BIO 14.6 hamster model offers distinct advantages for studying Delta-sarcoglycan deficiency compared to other muscular dystrophy models. This comparative analysis helps researchers select the most appropriate model for their specific research questions:

The BIO 14.6 hamster model is particularly valuable for studying sarcoglycan complex dynamics and testing gene therapy approaches, as evidenced by successful demonstration of functional rescue of the sarcoglycan complex using recombinant delta-SG adenovirus in this model .

What molecular mechanisms underlie the sarcolemmal instability in Delta-sarcoglycan deficiency?

The sarcolemmal instability observed in Delta-sarcoglycan deficiency involves complex molecular pathways. Current research indicates a cascade of events that leads to membrane damage and subsequent muscle degeneration:

• Primary Mechanisms:

  • Destabilization of the entire sarcoglycan complex (alpha, beta, gamma, and delta subunits)

  • Compromised association of alpha-dystroglycan with the sarcolemma

  • Disruption of the mechanical link between extracellular matrix and cytoskeleton

  • Increased susceptibility to mechanical stress during muscle contraction

• Secondary Consequences:

  • Abnormal calcium influx through membrane tears

  • Activation of calcium-dependent proteases

  • Mitochondrial dysfunction and oxidative stress

  • Inflammation and fibrosis

  • Progressive muscle fiber degeneration

• Molecular Signaling Alterations:

  • Dysregulation of mechanosensitive signaling pathways

  • Altered nitric oxide synthase localization and activity

  • Impaired satellite cell function affecting regeneration

  • Increased susceptibility to apoptotic signaling

Research using the BIO 14.6 hamster model has demonstrated that restoration of Delta-sarcoglycan expression can rescue the entire sarcoglycan complex and restore sarcolemmal integrity, confirming the central role of this protein in maintaining membrane stability .

What are the most effective readouts for assessing therapeutic efficacy in Delta-sarcoglycan deficiency models?

Evaluating therapeutic interventions in Delta-sarcoglycan deficiency models requires comprehensive assessment using multiple complementary readouts. Based on current research methodologies, the following approaches provide the most informative measures of efficacy:

• Molecular and Biochemical Markers:

  • Delta-sarcoglycan expression by immunoblotting and immunohistochemistry

  • Restoration of other sarcoglycan complex components

  • Alpha-dystroglycan sarcolemmal localization

  • Sarcolemmal proteins distribution pattern

• Structural Integrity Assessment:

  • Evans Blue dye uptake to evaluate membrane permeability

  • Serum creatine kinase levels as indicator of muscle damage

  • Histological analysis of muscle fiber morphology

  • Quantification of centrally nucleated fibers (regeneration)

  • Assessment of fibrotic tissue and fat infiltration

• Functional Measurements:

  • Grip strength testing

  • Treadmill exercise performance

  • Muscle-specific force production

  • Echocardiography for cardiac function (in models with cardiomyopathy)

• Long-term Outcome Indicators:

  • Survival rate

  • Body weight maintenance

  • Disease progression rate

  • Quality of life assessments

Studies in the BIO 14.6 hamster have demonstrated that muscle fibers expressing Delta-sarcoglycan following gene transfer lack morphological markers of muscular dystrophy and exhibit restored plasma membrane integrity, providing clear endpoints for therapeutic assessment .

How can researchers address the issue of immune responses against recombinant Delta-sarcoglycan in gene therapy approaches?

Immune responses against recombinant Delta-sarcoglycan represent a significant challenge in gene therapy approaches. Researchers can implement several strategies to mitigate these immune reactions:

• Vector Selection and Modification:

  • Use of low-immunogenic vectors (e.g., AAV9, AAV8)

  • Removal of viral genes that trigger immune responses

  • Inclusion of tissue-specific promoters to restrict expression

  • Capsid engineering to reduce recognition by neutralizing antibodies

• Immunomodulation Protocols:

  • Transient immunosuppression during initial vector administration

  • Use of corticosteroids or other immunosuppressive agents

  • B-cell depletion strategies to reduce antibody responses

  • Induction of tolerance through hepatic gene expression

• Delivery Optimization:

  • Local delivery to immune-privileged sites when possible

  • Gradual dose escalation protocols

  • Repeated low-dose administration rather than single high-dose

  • Route of administration optimization (intramuscular vs. intravenous)

• Protein Engineering Approaches:

  • Modification of immunogenic epitopes in Delta-sarcoglycan

  • Codon optimization to improve expression efficiency

  • Inclusion of regulatory sequences to modulate expression levels

Long-term expression of Delta-sarcoglycan has been demonstrated in the BIO 14.6 hamster model using recombinant adenoviral vectors, suggesting that effective strategies to overcome immune barriers are feasible .

What strategies can overcome the challenges of consistent Delta-sarcoglycan expression across different muscle groups?

Achieving consistent Delta-sarcoglycan expression across diverse muscle groups presents a significant challenge in therapeutic applications. Based on current research, the following methodological approaches can address this issue:

• Vector Distribution Optimization:

  • Systemic delivery via vascular routes with transient permeabilization

  • Use of serotypes with broad muscle tropism (AAV9, AAV8, AAV6)

  • Multiple injection sites for larger muscles

  • Consideration of developmentally appropriate delivery timing

• Expression Cassette Engineering:

  • Inclusion of muscle-specific enhancers for targeted expression

  • Use of hybrid promoters with activity across diverse muscle types

  • Incorporation of regulatory elements responsive to physiological cues

  • microRNA-based de-targeting from unwanted tissues

• Physiological Barriers Management:

  • Hydrodynamic delivery to enhance vascular permeability

  • Use of vascular permeabilizing agents (histamine, VEGF)

  • Consideration of extracellular matrix barriers in diseased muscle

  • Optimization of vector dose based on muscle mass and accessibility

• Assessment and Adaptation:

  • Real-time imaging to track vector distribution

  • Muscle-specific biomarkers to evaluate expression patterns

  • Adaptive dosing based on preliminary distribution data

  • Sequential targeting strategies for recalcitrant muscle groups

Research in the BIO 14.6 hamster model has shown the feasibility of widespread sarcoglycan complex restoration, suggesting that these technical challenges can be effectively addressed with optimized delivery approaches .

What are the most reliable methods for assessing the stability and functionality of recombinant Delta-sarcoglycan protein in vitro and in vivo?

Evaluating the stability and functionality of recombinant Delta-sarcoglycan requires rigorous methodological approaches in both in vitro and in vivo settings. The following techniques provide comprehensive assessment:

In Vitro Assessment Methods:

• Biochemical Stability:

  • Accelerated degradation studies at variable temperatures

  • Resistance to proteolytic enzymes

  • Circular dichroism spectroscopy for structural stability

  • Differential scanning calorimetry for thermal stability

  • Storage stability in various buffer conditions

• Functional Characterization:

  • Binding assays with other sarcoglycan components

  • Cell surface expression in transfected cells

  • Membrane incorporation efficiency

  • Glycosylation pattern analysis

  • Immunoprecipitation with complex partners

In Vivo Assessment Methods:

• Protein Expression and Localization:

  • Immunohistochemistry for sarcolemmal localization

  • Co-localization with other dystrophin-glycoprotein complex components

  • Quantitative assessment of expression duration

  • Analysis of expression in different muscle types

• Functional Restoration:

  • Rescue of the entire sarcoglycan complex

  • Restored association of alpha-dystroglycan with sarcolemma

  • Reduction in muscle fiber damage markers

  • Membrane integrity assessment with vital dyes

  • Force generation measurements of individual muscle groups

Research in the BIO 14.6 hamster has demonstrated that functional restoration can be effectively measured through these combined approaches, with particular emphasis on the ability of recombinant Delta-sarcoglycan to rescue the entire sarcoglycan complex and restore sarcolemmal integrity .

How might CRISPR-based approaches be applied for direct correction of Delta-sarcoglycan mutations?

CRISPR-based technologies offer promising avenues for direct correction of Delta-sarcoglycan mutations. While not directly addressed in the search results for SGCD, the following methodological framework can be applied based on similar gene editing approaches:

• Correction Strategies:

  • Homology-directed repair (HDR) for precise gene correction

  • Base editing for point mutations without double-strand breaks

  • Prime editing for targeted insertions/deletions without donor DNA

  • Exon skipping for mutations in non-essential exons

• Delivery Optimization:

  • AAV-mediated delivery of CRISPR components

  • Lipid nanoparticle formulations for improved targeting

  • In vivo electroporation for localized correction

  • Ex vivo correction in muscle stem cells followed by transplantation

• Safety Enhancement:

  • High-fidelity Cas9 variants to minimize off-target effects

  • Transient expression systems to limit editing activity

  • Tissue-specific promoters for restricted expression

  • Comprehensive off-target analysis using unbiased methods

• Efficacy Evaluation Framework:

  • Quantification of editing efficiency in target tissues

  • Assessment of corrected protein expression

  • Functional recovery measurements

  • Long-term stability of genetic correction

CRISPR/Cas9 systems have been successfully employed in Syrian hamsters for other genes, demonstrating the feasibility of applying these techniques to Delta-sarcoglycan mutations .

What potential exists for combining gene therapy with stem cell approaches in Delta-sarcoglycan deficiency?

Integrating gene therapy with stem cell approaches represents a promising frontier for treating Delta-sarcoglycan deficiency. This combinatorial strategy may overcome limitations of each individual approach:

• Methodological Framework:

  • Ex vivo correction of patient-derived myogenic stem cells

  • Expansion of genetically corrected cells

  • Transplantation into affected muscles

  • Potential systemic delivery for widespread distribution

• Cell Sources Optimization:

  • Satellite cells with inherent myogenic potential

  • Mesoangioblasts with ability to cross vascular barriers

  • Induced pluripotent stem cells (iPSCs) differentiated to myogenic lineage

  • CD133+ muscle-derived stem cells with regenerative capacity

• Technical Enhancements:

  • Bioengineered scaffolds to improve cell engraftment

  • Pro-survival factors to enhance transplanted cell viability

  • Development of migration-enhancing factors

  • Immunomodulation to prevent rejection of allogeneic cells

• Expected Outcomes:

  • Stable chimeric muscle with corrected cells

  • Continuous source of Delta-sarcoglycan expressing myoblasts

  • Enhanced regenerative capacity in damaged muscle

  • Long-term therapeutic benefit without repeated interventions

The successful demonstration of Delta-sarcoglycan gene transfer in the BIO 14.6 hamster model provides a foundation for exploring these combined approaches, potentially offering more durable therapeutic benefits for sarcoglycanopathies .

How can systems biology approaches enhance our understanding of Delta-sarcoglycan's role in the muscle membrane complex?

Systems biology offers powerful tools to elucidate the complex role of Delta-sarcoglycan within the broader context of muscle membrane biology. Implementing these approaches can reveal novel insights beyond traditional reductionist methods:

• Multi-omics Integration Strategies:

  • Transcriptomics to identify gene expression networks affected by Delta-SG deficiency

  • Proteomics to map interaction networks and post-translational modifications

  • Metabolomics to characterize metabolic alterations in diseased muscle

  • Integration of datasets to build comprehensive disease models

• Network Analysis Methodology:

  • Protein-protein interaction mapping focusing on sarcoglycan complex

  • Pathway enrichment analysis to identify affected biological processes

  • Network perturbation modeling to predict therapeutic targets

  • Comparison of network alterations across different muscular dystrophies

• Advanced Imaging Approaches:

  • Super-resolution microscopy of membrane complexes

  • Live-cell imaging to track dynamic interactions

  • Correlative light and electron microscopy for structural-functional correlation

  • Computational modeling of membrane complex assembly

• Functional Genomics Applications:

  • CRISPR screens to identify genetic modifiers of SGCD function

  • Synthetic lethality analysis to discover potential therapeutic targets

  • Comparative analysis across species to identify conserved functional domains

  • Analysis of splice variants and their functional implications

These integrated approaches would extend our understanding beyond the current knowledge that Delta-sarcoglycan is essential for maintaining sarcolemmal integrity, potentially revealing new therapeutic targets and biological mechanisms .